An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 382 participants.

Also called NCT03060577

  • Study
  • In this atlas

Overview

Design
Interventional study; non-randomized; no masking; primary purpose treatment
Phase
Phase 2
Enrolled
  • 382 participants (enrolled count) (from the registry)
Sponsor
  • Novartis Registry lists this organization as the lead sponsor
Registry
  • NCT NCT03060577
  • EudraCT 2016-003815-37
Other papers using this trial's data
  • Long-term efficacy and safety of inclisiran in patients with high cardiovascular risk and elevated LDL cholesterol (ORION-3): results from the 4-year open-label extension of the ORION-1 trial The lancet. Diabetes & endocrinology, 2023-02 DOI, PubMed 36620965

Courtesy of the U.S. National Library of Medicine.

Started
(actual) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Results first posted
(from the registry)
Countries
United States, Canada, Germany, Netherlands, United Kingdom (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT03060577. Non-randomized; no masking; primary purpose treatment. Start 2017-04-27 (actual); primary completion 2021-12-17 (actual). Results posted on 2023-03-24.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
An Extension Trial of Inclisiran in Participants With Cardiovascular Disease and High Cholesterol
Acronym
ORION-3
Condition
Atherosclerotic Cardiovascular Disease
Condition
Symptomatic Atherosclerosis
Condition
Type2 Diabetes
Intervention (Drug)
Inclisiran
Intervention (Drug)
Evolocumab
Lead sponsor
Novartis Pharmaceuticals (class: industry)

Record details

Record id
cardio:ct-nct03060577
Content hash
717da5bf7cb9e076f6ce38a886c70bb4e571163143f3d7fb5d98329195c5900c